The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells (original) (raw)

• Johnstone RW, Ruefli AA, Lowe SW . Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153–164.
  Article CAS PubMed Google Scholar
• Schimmer AD, Hedley DW, Penn LZ, Minden MD . Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001; 98: 3541–3553.
  Article CAS PubMed Google Scholar
• Wang X . The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922–2933.
  CAS PubMed Google Scholar
• Du C, Fang M, Li Y, Li L, Wang X . Smac, a mitochondrial protein that promotes cytochrome _c_-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42.
  Article CAS PubMed Google Scholar
• Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 45–53.
  Article Google Scholar
• Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441–446.
  Article CAS PubMed Google Scholar
• Igney FH, Krammer PH . Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002; 2: 277–288.
  Article CAS PubMed Google Scholar
• Cory S, Adams JM . The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–656.
  Article CAS PubMed Google Scholar
• Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705–711.
  Article CAS PubMed Google Scholar
• Gutierrez-Puente Y, Zapata-Benavides P, Tari AM, Lopez-Berestein G . Bcl-2-related antisense therapy. Semin Oncol 2002; 29: 71–76.
  Article CAS PubMed Google Scholar
• Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124–7129.
  Article CAS PubMed PubMed Central Google Scholar
• Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL . Multiple myeloma. Hematology 2001, 157–177.
• Strasser K, Ludwig H . Thalidomide treatment in multiple myeloma. Blood Rev 2002; 16: 207–215.
  Article PubMed Google Scholar
• Anderson KC, Boise LH, Louie R, Waxman S . Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12–25.
  Article PubMed Google Scholar
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.
  CAS PubMed Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–1534.
  Article CAS PubMed Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379.
  Article CAS PubMed PubMed Central Google Scholar
• Adams J . Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8: S49–S54.
  Article CAS PubMed Google Scholar
• LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996–5000.
  CAS PubMed Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–4427.
  Article CAS PubMed Google Scholar
• An B, Goldfarb RH, Siman R, Dou QP . Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062–1075.
  Article CAS PubMed Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.
  Article CAS PubMed Google Scholar
• Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST . A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79: 213–222.
  CAS PubMed Google Scholar
• Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001; 61: 5106–5115.
  CAS PubMed Google Scholar
• Dai Y, Landowski TH, Rosen ST, Dent P, Grant S . Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100: 3333–3343.
  Article CAS PubMed Google Scholar
• Leach JK, Tuyle GV, Lin PS, Schmidt-Ullrich R, Mikkelsen RB . Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 2001; 61: 3894–3901.
  CAS PubMed Google Scholar
• Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
  Article CAS PubMed Google Scholar
• Ao Y, Rohde LH, Naumovski L . p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. Oncogene 2001; 20: 2720–2725.
  Article CAS PubMed Google Scholar
• Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999; 274: 21155–21161.
  Article CAS PubMed Google Scholar
• An WG, Hwang SG, Trepel JB, Blagosklonny MV . Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276–1283.
  Article CAS PubMed Google Scholar
• Gross A, McDonnell JM, Korsmeyer SJ . BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899–1911.
  Article CAS PubMed Google Scholar
• Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH . Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805–813.
  Article CAS PubMed Google Scholar
• Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681–13686.
  Article CAS PubMed PubMed Central Google Scholar
• Frassanito MA, Cusmai A, Iodice G, Dammacco F . Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483–489.
  Article CAS PubMed Google Scholar
• Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC . Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607–612.
  Article CAS PubMed Google Scholar
• Chen J, Freeman A, Liu J, Dai Q, Lee RM . The apoptotic effect of HA14-1, a Bcl-2-molecular compound, requires Bax translocation and is enhanced by PK11195. Mol Cancer Ther 2002; 1: 961–967.
  PubMed Google Scholar
• McEnery MW, Snowman AM, Trifiletti RR, Snyder SH . Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci USA 1992; 89: 3170–3174.
  Article CAS PubMed PubMed Central Google Scholar
• Breitschopf K, Zeiher AM, Dimmeler S . Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000; 275: 21648–21652.
  Article CAS PubMed Google Scholar
• Li B, Dou QP . Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000; 97: 3850–3855.
  Article CAS PubMed PubMed Central Google Scholar
• Chadebech P, Brichese L, Baldin V, Vidal S, Valette A . Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem Biophys Res Commun 1999; 262: 823–827.
  Article CAS PubMed Google Scholar
• Mahyar-Roemer M, Roemer K . p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001; 20: 3387–3398.
  Article CAS PubMed Google Scholar
• Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 2002; 21: 3611–3619.
  Article CAS PubMed Google Scholar
• Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T . Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol 2000; 20: 7311–7318.
  Article CAS PubMed PubMed Central Google Scholar
• Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. Requirement of JNK for stress-induced activation of the cytochrome _c_-mediated death pathway. Science 2000; 288: 870–874.
  Article CAS PubMed Google Scholar
• Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N et al. JNK-dependent release of mitochondrial protein, SMAC during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003; 278: 17593–17596.
  Article CAS PubMed Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 3: 577–590.
  Article Google Scholar
• Amstad PA, Liu H, Ichimiya M, Berezesky IK, Trump BF, Buhimschi IA et al. BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production. Redox Rep 2001; 6: 351–362.
  Article CAS PubMed Google Scholar
• Lezoualc'h F, Sagara Y, Holsboer F, Behl C . High constitutive NF-kappaB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 1998; 18: 3224–3232.
  Article CAS PubMed PubMed Central Google Scholar
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647.
  Article CAS PubMed Google Scholar
• Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929–3938.
  CAS PubMed Google Scholar
• van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM . Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211–219.
  Article CAS PubMed Google Scholar
• Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425–432.
  Article CAS PubMed Google Scholar
• Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679–683.
  CAS PubMed Google Scholar
• Liu Q, Gazitt Y . Potentiation of dexamethasone, taxel, and Ad-p53-induced apoptosis by Bcl-2 anti-sense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 2003; 101: 4105–4114.
  Article CAS PubMed Google Scholar
• Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001; 3: 173–182.
  Article CAS PubMed Google Scholar
• Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99: 3461–3464.
  Article CAS PubMed Google Scholar
• Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN . Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1 and Src kinases. Blood 2003; 102: 269–275.
  Article CAS PubMed Google Scholar